Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

LMP2-specific T-cell receptor-transduced autologous T lymphocytes

A preparation of autologous T lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the Epstein-Barr virus (EBV) latent membrane protein (LMP) 2, with potential immunomodulating and antineoplastic activities. Upon administration, LMP2-specific TCR-transduced autologous T lymphocytes recognize and bind to LMP2, which may promote cell death and inhibit the growth of tumor cells expressing LMP2. LMP2 is expressed in various EBV-associated malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	LMP2 antigen-specific TCR T cells

LMP2-specific T-cell receptor-transduced autologous T lymphocytes

Search NCI's Drug Dictionary